公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2010 | O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers | PEI-FANG WU; KUAN-TING KUO ; LU-TING KUO ; YI-TING LIN; WEI-CHUNG LEE; YEN-SHEN LU ; CHIH-HSIN YANG ; RUEY-MEEI WU ; YONG-KWANG TU ; JUI-CHANG TASI ; HAM-MIN TSENG; SHENG-HONG TSENG ; ANN-LII CHENG ; CHING-HUNG LIN | Lung Cancer | 26 | 26 | |
2010 | Octogenarians with advanced non-small cell lung cancer: Treatment modalities, survival, and prognostic factors | KUAN-YU CHEN ; JEN-HAU CHEN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | Journal of Thoracic Oncology | 17 | 14 | |
2019 | Opportunities of circulating tumor DNA in lung cancer | Wu T.-H; Hsiue E.H.-C; CHIH-HSIN YANG | Cancer Treatment Reviews | 14 | 14 | |
2017 | Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy | BIN-CHI LIAO ; Chia-Chi Lin ; JIH-HSIANG LEE ; CHIH-HSIN YANG | Lung Cancer | 38 | 35 | |
2011 | Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations | CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 10 | 10 | |
2023 | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON | Hartmaier, Ryan J; Markovets, Aleksandra A; Ahn, Myung Ju; Sequist, Lecia V; Han, Ji-Youn; Cho, Byoung Chul; Yu, Helena A; Kim, Sang-We; CHIH-HSIN YANG ; Lee, Jong-Seok; Su, Wu-Chou; Kowalski, Dariusz M; Orlov, Sergey; Ren, Song; Frewer, Paul; Ou, Xiaoling; Cross, Darren A E; Kurian, Nisha; Cantarini, Mireille; Jänne, Pasi A | Cancer discovery | 36 | 29 | |
2018 | Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer | Ramalingam S.S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A. | Journal of Clinical Oncology | 401 | 346 | |
2023 | Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies | Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B; Ramalingam, Suresh S; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; CHIH-HSIN YANG | Targeted oncology | 2 | 5 | |
2020 | Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study | CHIH-HSIN YANG ; Kim, Sang-We; Kim, Dong-Wan; Lee, Jong-Seok; Cho, Byoung Chul; Ahn, Jin-Seok; Lee, Dae H.; Kim, Tae Min; Goldman, Jonathan W.; Natale, Ronald B.; Brown, Andrew P.; Collins, Barbara; Chmielecki, Juliann; Vishwanathan, Karthick; Mendoza-Naranjo, Ariadna; Stathes Paganis | Journal of Clinical Oncology | 213 | 189 | |
2019 | Osimertinib in patients with T790M mutation-positive, advanced non–small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies | Ahn M.-J; Tsai C.-M; Shepherd F.A; Bazhenova L; Sequist L.V; Hida T; CHIH-HSIN YANG ; Ramalingam S.S; Mitsudomi T; Jnne P.A; Mann H; Cantarini M; Goss G. | Cancer | 120 | 111 | |
2020 | Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies | Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG ; Mitsudomi T.; Lee J.S. | Cancer Research and Treatment | 5 | 5 | |
2017 | Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component | CHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A. | Journal of Clinical Oncology | 454 | 443 | |
2019 | Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report | Chih-Hsin CHIH-HSIN YANG ; Shepherd F.A; Kim D.-W; Lee G.-W; Lee J.S; Chang G.-C; Lee S.S; Wei Y.-F; Lee Y.G; Laus G; Collins B; Pisetzky F; Horn L. | Journal of Thoracic Oncology | 148 | 126 | |
2020 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study | Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG ; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. | The Lancet Oncology | 297 | 252 | |
2022 | Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B) | CHIH-HSIN YANG ; Ohe, Yuichiro; Chiu, Chao-Hua; Ou, Xiaoling; Cantarini, Mireille; Jänne, Pasi A; Hartmaier, Ryan J; Ahn, Myung Ju | Clinical cancer research : an official journal of the American Association for Cancer Research | 7 | 5 | |
2023 | Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC | Planchard, David; Jänne, Pasi A; Cheng, Ying; CHIH-HSIN YANG ; Yanagitani, Noriko; Kim, Sang-We; Sugawara, Shunichi; Yu, Yan; FAN YUN ; Geater, Sarayut L; Laktionov, Konstantin; Lee, Chee K; Valdiviezo, Natalia; Ahmed, Samreen; Maurel, Jean-Marc; Andrasina, Igor; Goldman, Jonathan; Ghiorghiu, Dana; Rukazenkov, Yuri; Todd, Alex; Kobayashi, Kunihiko | The New England journal of medicine | 23 | | |
2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
2018 | Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study | CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHAO-CHI HO ; WEI-YU LIAO ; JIH-HSIANG LEE ; TZU-HSIU TSAI ; KANG-YI SU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Bai Y.-Y.; DE-RUI HUANG ; Thress K.S.; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 120 | 109 | |
2018 | Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors | BIN-CHI LIAO ; Bai Y.-Y; JIH-HSIANG LEE ; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG | Journal of the Formosan Medical Association | 11 | 9 | |
2018 | Overview of current systemic management of EGFR-mutant NSCLC | Hsu W.-H; CHIH-HSIN YANG ; Mok T.S; Loong H.H. | Annals of Oncology | 212 | 176 | |